US20050272654A1 - NF-kappaB activation inhibitors, and their pharmaceutical uses - Google Patents
NF-kappaB activation inhibitors, and their pharmaceutical uses Download PDFInfo
- Publication number
- US20050272654A1 US20050272654A1 US11/144,889 US14488905A US2005272654A1 US 20050272654 A1 US20050272654 A1 US 20050272654A1 US 14488905 A US14488905 A US 14488905A US 2005272654 A1 US2005272654 A1 US 2005272654A1
- Authority
- US
- United States
- Prior art keywords
- cells
- activation
- hgh
- erythropoietin
- daunomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 title claims description 24
- 239000003112 inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 18
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 230000003211 malignant effect Effects 0.000 claims abstract description 8
- 230000007170 pathology Effects 0.000 claims abstract description 6
- 230000004913 activation Effects 0.000 claims abstract description 5
- 102000003945 NF-kappa B Human genes 0.000 claims abstract 7
- 108010057466 NF-kappa B Proteins 0.000 claims abstract 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 31
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 30
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 30
- 102000003951 Erythropoietin Human genes 0.000 claims description 20
- 108090000394 Erythropoietin Proteins 0.000 claims description 20
- 229940105423 erythropoietin Drugs 0.000 claims description 20
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 229930012538 Paclitaxel Natural products 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 claims description 9
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 claims description 9
- 102000044890 human EPO Human genes 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 8
- 229960003048 vinblastine Drugs 0.000 claims description 8
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 8
- 229960004528 vincristine Drugs 0.000 claims description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 238000002483 medication Methods 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 59
- 108010000521 Human Growth Hormone Proteins 0.000 description 34
- 102000002265 Human Growth Hormone Human genes 0.000 description 33
- 239000000854 Human Growth Hormone Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 22
- 102000018997 Growth Hormone Human genes 0.000 description 20
- 108010051696 Growth Hormone Proteins 0.000 description 20
- 239000000122 growth hormone Substances 0.000 description 19
- 208000006265 Renal cell carcinoma Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
- 101150066553 MDR1 gene Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000027257 transmembrane receptors Human genes 0.000 description 3
- 108091008578 transmembrane receptors Proteins 0.000 description 3
- 230000001173 tumoral effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100021592 Interleukin-7 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical class N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- -1 NF-κB inhibitor compounds Chemical class 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229940063153 saizen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention has for its object the use of biological inhibitors of NF- ⁇ B, in the field of treating cancers, and more particularly malignant hemopathies or solid tumors.
- the expression of the MDRs is controlled by different nuclear factors.
- the MDR1 gene has in its regulatory portion binding sites of the NF- ⁇ B factor (Zhou G, Kuo M T, 1997, J Biol Chem, 272:15174-15183).
- This nuclear factor which moreover plays a considerable role in numerous inflammatory situations (Barnes P J, Karin M, 1997, N Engl J Med, 336:1066-1071) participates in the activation of the MDR1 gene.
- the present invention results from the discovery by the inventors of new effects of the human growth hormone (HGH), also called somatotropin, namely, on the one hand that HGH, and other compounds connected specifically to the transmembrane receptors of class I cytokines, are inhibitors of the activation of NF- ⁇ B by a cytotoxic molecule, and, on the other hand, that HGH, and other above-mentioned compounds, permit potentiating the effects of cytotoxic molecules and hence reducing the concentrations of these latter in the field of therapeutic treatments.
- HGH human growth hormone
- somatotropin also called somatotropin
- the inventors have observed that the human monocytes respond less to a stimulation by lipopolysaccharides (LPS) when they are cultivated in the presence of exogenous recombinant HGH.
- LPS lipopolysaccharides
- the inventors discovered that the human monocytes died after bridging (or engagement) of the surface molecule AP01/CD95/Fas, and have shown that HGH decreases the death mediated through the molecule Fas, by increasing the synthesis of an antiapoptogenic proto-oncogene Bcl-2.
- the inventors have studied the effects of HGH on the ⁇ -TNF response, because Fas and the p55 receptor of the ⁇ -TNF belong to the same family of nerve growth receptors.
- the human promyeloid leukemic line U937 has been used to carry out this work, because of the insensitivity of human monocytes to the death mediated by ⁇ -TNF.
- Fas namely that HGH accelerates the death of these cells mediated by ⁇ -TNF, has permitted the inventors to conclude as to the inhibitory effect of HGH on the activation of NF- ⁇ B by ⁇ -TNF, or by other cytotoxic molecules activating NF- ⁇ b, such as daunomycin.
- the present invention has for its object to provide a new method for the treatment of cancers, and more particularly malignant hemopathies and solid tumors, offering the advantage of improving both the response of the sick person to certain anti-cancer treatments and also, potentially, the general condition of the sick person.
- the invention also has for its object to provide new products for the treatment of said pathologies, having both the advantage of increasing the tumoral cell response to chemotherapy, and to improve the general condition of the patients.
- the new products of the invention permit decreasing the activation of the NF- ⁇ B factor by means of the compound that is used to inhibit the activation of NF- ⁇ B, such as the human growth hormone, which is adapted to give rise to the inhibition of the transcription of the MDR genes and hence a reinforcement of the cytotoxic effects of the anti-tumor agents used, with the expected result of decreasing the dosage of these anti-tumor medications.
- the invention has for its object the use of compounds inhibiting the activation of NF- ⁇ B, for the preparation of medications adapted for the treatment of malign hemopathies and solid tumors.
- the invention more particularly has for its object the use of NF- ⁇ B inhibitor compounds, for the preparation of medications for the prevention of the appearance or the treatment of phenomena of resistance to cytotoxic molecules used in the field of treatment of the above-mentioned pathologies, these resistance phenomena arising in patients treated with these molecules when these latter are adapted to activate NF- ⁇ B.
- NF- ⁇ B inhibitor compounds any compound capable of inhibiting in the cells of the organism, the activation of NF- ⁇ B caused by the cytotoxic molecules used in the field of treatment of the above-mentioned pathologies, and hence any compound capable of inhibiting the synthesis of proteins (such as P-gp) permitting the cells to eliminate the molecules before they can reach their molecular targets.
- the invention relates more particularly to the above-mentioned use of compounds inhibiting the activation of NF- ⁇ B, in association with one or several cytotoxic molecules usable in the field of treatment of malign hemopathies or solid tumors, said cytotoxic molecules being adapted to activate the NF- ⁇ B factor.
- the compounds inhibiting the activation of NF- ⁇ B used in the scope of the present invention are compounds binding specifically to the transmembrane receptors of the cytokines of class I in the cells of the organism.
- said compounds are selected from those binding to the above-mentioned receptors whose amino acid sequences of the transmembrane, intracytoplasmic and extramembrane portions have a homology of about 50% to about 70%.
- the invention has more particularly for its object the above-mentioned use of compounds inhibiting the activation of NF- ⁇ B as defined above, selected from growth hormone, prolactin, erythropoietin, interleukin-4, interleukin-7, G-CSF, GM-CSF, interleukin-3, interleukin-6, of human or other mammal origin.
- said compounds are selected from growth hormone or erythropoietin.
- the recombinant human growth hormone as encoded by the nucleotide SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence in amino acids is represented by SEQ ID NO 2, said growth hormone being obtained by transformation of suitable cells with the help of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification.
- the invention also relates to the above-mentioned use, of any peptide sequence derived by addition and/of deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2, and conserving the property of the human growth hormone of inhibiting the activation of NF- ⁇ B.
- the invention has more particularly for its further object the above-mentioned use of recombinant human erythropoietin such as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin, whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the aid of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification.
- the invention also relates to the above-mentioned use, of any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of human erythropoietin of inhibiting the activation of NF- ⁇ B.
- the invention has more particularly for its object the above-mentioned use of compounds inhibiting the activation of NF- ⁇ B as defined above, for the preparation of a medication administrable by the parenteral route (IM, IV, SC), particularly in the amount of:
- cytotoxic molecules adapted to activate the NF- ⁇ B factor used in association with said compounds inhibiting the activation of NF- ⁇ B can be cited:
- anthracyclines of which may be mentioned daunomycin, and dauxorubicin,
- the vinca-alkaloids such as vinblastine and vincristin
- paclitaxel or Taxol, DCI.
- the dosage of the cytotoxic molecules used in association with said compounds is about 2 to about 5 times less than the dosage of these same molecules used alone in the scope of the treatment of malignant hemopathies and solid tumors.
- the usual daily dose of daunomycin or dauxorubicin being from 40 to 60 mg/m 2
- the dosage of these latter in the scope of the present invention is about 5 to 30 mg/m 2
- the usual daily dosage of vinblastine being from 5 to 7 mg/m 2
- the dosage of this latter in the scope of the present invention is about 1 to 4 mg/m 2
- the usual daily dosage of vincristin being from 1 to 2 mg/m 2
- the dosage of this latter in the scope of the present invention is about 0.1 to 1 mg/m 2
- the usual daily dosage of taxol being about 75 mg/m 2
- the dosage of this latter in the scope of the present invention is about 15 to 35 mg/m 2 .
- malignant hemopathies such as leukemias, lymphomas,
- solid tumors such as those of the ovary or the breast.
- the invention also has for its object any product containing:
- a compound inhibiting the activity of NF- ⁇ B such as described above, and more particularly a compound binding specifically to the transmembrane receptors of the class I cytokines as defined above,
- cytotoxic molecule adapted to activate the NF- ⁇ B factor
- the invention also has for its object any product as defined above, as a combined preparation for simultaneous use, separate or over time, for the prevention of the appearance, or for the treatment, of phenomena of resistance to cytotoxic molecules used in the scope of treatment of the above-mentioned pathologies, appearing in patients treated with molecules when these latter are adapted to activate NF- ⁇ B.
- the invention relates more particularly to any product as defined above, characterized in that it comprises as a compound inhibiting the activation of NF- ⁇ B, growth hormone, prolactin, erythropoietin, interleukin-4, interleukin-7, G-CSF, GM-CSF, interleukin-3, interleukin-6.
- Products particularly preferred in the scope of the present invention are those comprising as a compound inhibiting the activation of NF- ⁇ B, growth hormone or erythropoietin.
- the invention has more particularly for its object any product as defined above, characterized in that it comprises:
- recombinant human growth hormone as described above, encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence of amino acids is represented by SEQ ID NO 2, or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2, and preserving the property of human growth hormone to inhibit the activation of NF- ⁇ B.
- the invention also has for its object any product as defined above, characterized in that it comprises recombinant human erythropoietin such as described above encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of human erythropoietin to inhibit the activation of NF- ⁇ B.
- the invention also relates to any product as described above, characterized in that it comprises as cytotoxic molecule adapted to activate the NF- ⁇ B factor, any molecule selected from the following:
- anthracyclines such as daunomycin or dauxorubicin
- vinca-alkaloids such as vinblastine and vincristine
- paclitaxel or Taxol, DCI.
- Products such as those defined above that are preferred in the scope of the present invention are characterized in that they contain:
- growth hormone and daunomycin or dauxorubicin in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 5 to 30 mg/m 2 of daunomycin or dauxorubicin,
- growth hormone and vinblastine in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 1 to 4 mg/m 2 of vinblastine,
- growth hormone and vincristine in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 0.1 to 1 mg/m 2 of vincristine,
- growth hormone and taxol in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 15 to 35 mg/m 2 of taxol,
- erythropoietin and daunomycin or dauxorubicin in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 5 to 3 mg/m 2 of daunomycin or dauxorubicin,
- erythropoietin and vinblastine in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 1 to 4 mg/m 2 of vinblastine,
- erythropoietin and vincristine in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 0.1 to 1 mg/m 2 of vincristine,
- erythropoietin and taxol in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 15 to 35 mg/m 2 of taxol.
- FIG. 1 The effect of growth hormone on the mortality of cells exposed to ⁇ -TNF: the percentage of the dead cells (IP+) is indicated on the ordinate, the white colonies corresponding to the cells of the strain U937-Neo, the black colonies corresponding to the cells of the strain U937-hGH; the concentrations of NFT- ⁇ are indicated on the abscissa in IU/ml.
- FIG. 2 The effect of growth hormone on the translocation of NF- ⁇ B; column 1 corresponds to the control cells U937, column 2 corresponds to the U937 cells treated with ⁇ -TNF+cycloheximide, column 3 corresponds to the U937 cells treated with ⁇ -TNF, column 4 corresponds to the U937 cells treated with ⁇ -TNF+a mutant NF- ⁇ B probe, column 5 corresponds to the U937 cells treated with ⁇ -TNF+a homologous NF- ⁇ B probe, column 6 corresponds to the control cells U937-HGH, column 7 corresponds to the U937-HGH cells treated with ⁇ -TNF+cycloheximide, column 8 corresponds to the U937-HGH cells treated with ⁇ -TNF; the presence of NF- ⁇ B is indicated by an arrow.
- FIG. 3 Effect of growth hormone on the reporter activity CAT; the percentage of variation of CAT activity is indicated on the abscissa; the two left columns show the two experiments carried out on U937-Neo cells, and the two right columns represent the two independent experiments carried out on U937-HGH cells.
- FIG. 4 Effect of growth hormone on apoptosis induced by daunomycin; the percentage of the dead cells (IP+) is indicated on the ordinate, the white columns corresponding to the cells of the strain U937-Neo, the black columns corresponding to the cells of the strain U937-HGH; the indicated percentages show the increase of mortality of the cells; the concentrations of daunomycin are indicated on the abscissa in ⁇ M.
- FIG. 5 Effect of growth hormone on the apoptosis of the IGROV/ADR line, induced by daunomycin; the percentage of dead cells (IP+) is indicated on the ordinate, and different columns corresponding to the different concentrations of HGH used (0, 5, 50, 500, 1000 ng/ml); the concentrations of daunomycin are indicated on the abscissa in ⁇ M.
- FIG. 6 Effect of erythropoietin on the apoptosis of the human renal carcinoma line HIEG, induced by daunomycin: for each of the experiments 1 and 2, the number of living cells is indicated on the ordinate, the white columns correspond to the RCC-Neo cells, the black columns correspond to the RCC-EPO cells; the concentrations of daunomycin are indicated on the abscissa in ⁇ M.
- the invention is illustrated with the help of the following detailed description of the in vitro effect of growth hormone and erythropoietin on tumoral cell lines.
- a selection gene (neomycin resistant, NeOR) and the gene encoding for human growth hormone (HGH) have been co-transfected in the human promyeloid leukemic line U937.
- HGH human growth hormone
- This cytokine secreted by different types of immune cells has an anti-tumor activity (Harakana, K et al., 1984, Int J Cancer, 34:263-267) and is capable of promoting the activation of NF- ⁇ B (Baeuerle P A, Henkel T, 1994, Ann Rev Immunol, 12:141-179).
- the U937-HGH cells and the U937-Neo control cells have been cultured for 48 hours in the presence of increasing concentrations of recombinant ⁇ -TNF.
- the washed cells have been incubated in the presence of propidium iodide which is incorporated in the DNA of the dead cells. These cells are analyzed by flowing cytometry.
- FIG. 1 shows the increase of the incorporation of propidium iodide as a function of increasing doses of ⁇ -TNF expressed in international units (IU).
- IU international units
- FIG. 2 shows the result of an analysis by gel delay.
- U937-HGH and U937 cells the mother line having served for obtaining the U937-HGH lines
- inductors including ⁇ -TNF or ⁇ -TNF and cycloheximide (inhibitor of protein synthesis).
- This experiment indicates clearly that the presence of NF- ⁇ B in the nuclei of the U937-HGH cells, is decreased relative to the control cells.
- NF- ⁇ B The presence of NF- ⁇ B is seen in lines 4 and 5, which represent the migration of the nuclear extracts of U937 cells stimulated by ⁇ -TNF, and pre-incubated, either with a cold probe muted NF- ⁇ B which does not displace the signal (line 4), or with a cold probe NF- ⁇ B homolog which inhibits the signal (line 5).
- FIG. 3 shows the result of an enzyme immunoassay (ELISA) carried out with the lysate of U937-HGH and U937-Neo cells transfected in a transitory manner with a plasmid containing NF- ⁇ B sequences in the promotor of the reporter gene encoding for chloramphenicol-acetyl-transferase (CAT) (Chiao P et coll., 1994, Proc Natl Acad Sci USA, 91:28-32).
- ELISA enzyme immunoassay
- the cells are transfected by electroporation then incubated with ⁇ -TNF. At the end of culturing, the cells are lysated and the activated CAT is measured by an commercial ELISA (Boehringer-Mannheim) according to the directions of the supplier.
- the figure shows that the CAT activity, reflected by the presence of NF- ⁇ B, is decreased in the U937-HGH cells relative to the control cells, after stimulation by ⁇ -TNF.
- FIGS. 2 and 3 therefore show by two different methodological approaches, that the synthesis of NF- ⁇ B is decreased in U937-HGH relative to the control line.
- ⁇ -TNF is very difficult in human clinical work because of the adverse side effects, the inventors are interested in daunomycin.
- This anthracyclin used in anti-cancer therapy under the name of Cerubidine ⁇ acts by insertion in the cellular DNA sequences, thus disturbing the cellular function.
- Cerubidine ⁇ acts by insertion in the cellular DNA sequences, thus disturbing the cellular function.
- daunomycin activates NF- ⁇ B (Das K C, White C W, 1997, J Biol Chem, 272:14914-14920).
- FIG. 4 indicates that the U937-HGH line is also more sensitive than the control line to the mediated death by daunomycin.
- HGH human ovarian adenocarcinoma IGROV/ADR
- these cells are insensitive to the toxic effect of the daunomycin added to the culture (HGH groups 0 ng/ml).
- the addition of recombinant HGH renders these cells sensitive to daunomycin, with a maximum effect observed for the lowest dose of HGH used here, namely 5 ml/ml.
- EPO Erythropoietin
- RCC-EPO cells 4.10 4 RCC cells have been transfected in a transitory manner with the help of an Effecten ⁇ kit, or with 3 ⁇ g of plasmid carrying the gene encoding for EPO (RCC-EPO cells), or with 3 ⁇ g of a plasmid coding for the resistance to neomycin (RCC-Neo cells) as the negative control. After 48 hours, the RCC were combined with daunomycin at two different concentrations: 0.3 and 0.6 ⁇ M. The number of surviving cells was measured 48 hours later by flow cytometry (FIG. 6).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compounds inhibiting the activation of the nuclear factor κB (NF-κB) are used for the preparation of medications adapted for the treatment of malignant hemopathies and solid tumors, and for the prevention of the appearance or the treatment, of phenomena of resistance to cytotoxic molecules used in the scope of treatment of the above pathologies, appearing in patients treated with these molecules when the latter are adapted to activate NF-κB.
Description
- This application is a division of co-pending application Ser. No. 09/856,796, filed on May 25, 2001, the entire contents of which are hereby incorporated by reference.
- 1. Field of the Invention
- The present invention has for its object the use of biological inhibitors of NF-κB, in the field of treating cancers, and more particularly malignant hemopathies or solid tumors.
- 2. Description of Related Art
- Numerous tumoral cells have developed sophisticated mechanisms permitting them to resist the effect of certain agents used in anti-cancer chemotherapy. One of the counter-measures at present developed by clinicians is the increase of the dosage of these medications, with the result of aggravating the side effects observed in the patients. Thus, for example, most of the leukemias and certain lymphomas are treated by the administration of anthracyclines (daunomycin, dauxorubicin) whose toxicity is manifest in the vital functions (hepatic, cardiac . . . ) (Gauthier, P H, 1987, Gas Med Fr, 94:43-49).
- The mechanism of action of the medications has been well studied and has essentially led to the death of tumor cells by apoptosis (Hannum Y A, Blood, 89:1845-1853). To avoid apoptosis, the cells use a category of proteins encoded by genes called multidrug resistant genes (MDR) which permit them to control the intake or outflow of various molecules (Pastan I, Gottesman M M, 1991, Annu Rev Med, 42:277-286). In the case of anti-cancer agents, these are actively evacuated by means of P-glycoprotein (P-gp), produced by the MDR1 gene.
- As all genes, the expression of the MDRs is controlled by different nuclear factors. Thus, it has been recently shown that the MDR1 gene has in its regulatory portion binding sites of the NF-κB factor (Zhou G, Kuo M T, 1997, J Biol Chem, 272:15174-15183). This nuclear factor, which moreover plays a considerable role in numerous inflammatory situations (Barnes P J, Karin M, 1997, N Engl J Med, 336:1066-1071) participates in the activation of the MDR1 gene.
- Several recent works have established a connection between the inhibition and the activation of NF-κB and the potentialization of apoptosis. In the first reported experiments (Wang C Y et coll., 1996, Science, 272:784-786, Van Antwerp D J et coll., Science, 272:787-789) the authors have validated their data by using genetically manipulated lines to obtain the inhibition or the overexpression of NF-κB activity. Thus, this does not permit their direct use in therapeutic applications.
- In another study, the authors have tested the effects of different protease inhibitors preventing the activation of NF-κB (pyrolidine dithiocarbamate, N-tosyl-L-lysl chloromethylcetone, N-acetyl cysteine) on a line of murine macrophages (Mannick E E et coll., 1997, Mediators of Inflammation, 6:225-232). The authors of this article conclude there is a possible connection between NF-κB inhibition and the induction of apoptosis of the inflammatory and immune cells.
- Finally, another approach based on inhibition of the inflammatory effects of NF-κB, consists in overexpressing the natural inhibitor of NF-κB, the IκB molecule, by gene therapy (Makarov S S et coll., 1997, Gene Ther, 4:846-852). This technology is also in the state of development because of the complexity and the vectorization necessary for its good operation.
- The present invention results from the discovery by the inventors of new effects of the human growth hormone (HGH), also called somatotropin, namely, on the one hand that HGH, and other compounds connected specifically to the transmembrane receptors of class I cytokines, are inhibitors of the activation of NF-κB by a cytotoxic molecule, and, on the other hand, that HGH, and other above-mentioned compounds, permit potentiating the effects of cytotoxic molecules and hence reducing the concentrations of these latter in the field of therapeutic treatments.
- First of all, the inventors have observed that the human monocytes respond less to a stimulation by lipopolysaccharides (LPS) when they are cultivated in the presence of exogenous recombinant HGH. The inventors have accordingly concluded that HGH inhibits the activation of NF-κB after stimulation by LPS (Haeffner A et coll., 1997, J Immunol, 158:1310-1314).
- Then, the inventors discovered that the human monocytes died after bridging (or engagement) of the surface molecule AP01/CD95/Fas, and have shown that HGH decreases the death mediated through the molecule Fas, by increasing the synthesis of an antiapoptogenic proto-oncogene Bcl-2.
- Finally, the inventors have studied the effects of HGH on the α-TNF response, because Fas and the p55 receptor of the α-TNF belong to the same family of nerve growth receptors. The human promyeloid leukemic line U937 has been used to carry out this work, because of the insensitivity of human monocytes to the death mediated by α-TNF. Obtaining results opposite those observed with Fas, namely that HGH accelerates the death of these cells mediated by α-TNF, has permitted the inventors to conclude as to the inhibitory effect of HGH on the activation of NF-κB by α-TNF, or by other cytotoxic molecules activating NF-κb, such as daunomycin.
- Thus, the present invention has for its object to provide a new method for the treatment of cancers, and more particularly malignant hemopathies and solid tumors, offering the advantage of improving both the response of the sick person to certain anti-cancer treatments and also, potentially, the general condition of the sick person.
- The invention also has for its object to provide new products for the treatment of said pathologies, having both the advantage of increasing the tumoral cell response to chemotherapy, and to improve the general condition of the patients. The new products of the invention permit decreasing the activation of the NF-κB factor by means of the compound that is used to inhibit the activation of NF-κB, such as the human growth hormone, which is adapted to give rise to the inhibition of the transcription of the MDR genes and hence a reinforcement of the cytotoxic effects of the anti-tumor agents used, with the expected result of decreasing the dosage of these anti-tumor medications.
- The invention has for its object the use of compounds inhibiting the activation of NF-κB, for the preparation of medications adapted for the treatment of malign hemopathies and solid tumors.
- The invention more particularly has for its object the use of NF-κB inhibitor compounds, for the preparation of medications for the prevention of the appearance or the treatment of phenomena of resistance to cytotoxic molecules used in the field of treatment of the above-mentioned pathologies, these resistance phenomena arising in patients treated with these molecules when these latter are adapted to activate NF-κB.
- By compounds inhibiting the activation of NF-κB (also called NF-κB inhibitor compounds), there is meant any compound capable of inhibiting in the cells of the organism, the activation of NF-κB caused by the cytotoxic molecules used in the field of treatment of the above-mentioned pathologies, and hence any compound capable of inhibiting the synthesis of proteins (such as P-gp) permitting the cells to eliminate the molecules before they can reach their molecular targets.
- The invention relates more particularly to the above-mentioned use of compounds inhibiting the activation of NF-κB, in association with one or several cytotoxic molecules usable in the field of treatment of malign hemopathies or solid tumors, said cytotoxic molecules being adapted to activate the NF-κB factor.
- Preferably, the compounds inhibiting the activation of NF-κB used in the scope of the present invention, are compounds binding specifically to the transmembrane receptors of the cytokines of class I in the cells of the organism. Preferably, said compounds are selected from those binding to the above-mentioned receptors whose amino acid sequences of the transmembrane, intracytoplasmic and extramembrane portions have a homology of about 50% to about 70%.
- The invention has more particularly for its object the above-mentioned use of compounds inhibiting the activation of NF-κB as defined above, selected from growth hormone, prolactin, erythropoietin, interleukin-4, interleukin-7, G-CSF, GM-CSF, interleukin-3, interleukin-6, of human or other mammal origin.
- Preferably, said compounds are selected from growth hormone or erythropoietin.
- In this connection the invention has more particularly for its object the above-mentioned use:
- of human growth hormone, as obtained by extraction from hypophysary extracts, and purification,
- or, preferably, of the recombinant human growth hormone as encoded by the nucleotide
SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence in amino acids is represented bySEQ ID NO 2, said growth hormone being obtained by transformation of suitable cells with the help of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification. - The invention also relates to the above-mentioned use, of any peptide sequence derived by addition and/of deletion and/or substitution of one or several amino acids of the sequence
SEQ ID NO 2, and conserving the property of the human growth hormone of inhibiting the activation of NF-κB. - The invention has more particularly for its further object the above-mentioned use of recombinant human erythropoietin such as encoded by the nucleotide sequence
SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin, whose sequence in amino acids is represented bySEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the aid of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification. - The invention also relates to the above-mentioned use, of any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence
SEQ ID NO 4, and preserving the property of human erythropoietin of inhibiting the activation of NF-κB. - The invention has more particularly for its object the above-mentioned use of compounds inhibiting the activation of NF-κB as defined above, for the preparation of a medication administrable by the parenteral route (IM, IV, SC), particularly in the amount of:
- about 2 IU/kg of body weight/day in the case of human growth hormone,
- of about 150 IU/kg of body weight/day in the case of human erythropoietin.
- Among the cytotoxic molecules adapted to activate the NF-κB factor used in association with said compounds inhibiting the activation of NF-κB within the scope of the present invention, can be cited:
- the cytokines,
- the anthracyclines, of which may be mentioned daunomycin, and dauxorubicin,
- the vinca-alkaloids, such as vinblastine and vincristin,
- paclitaxel (or Taxol, DCI).
- Preferably, the dosage of the cytotoxic molecules used in association with said compounds is about 2 to about 5 times less than the dosage of these same molecules used alone in the scope of the treatment of malignant hemopathies and solid tumors.
- By way of illustration:
- the usual daily dose of daunomycin or dauxorubicin being from 40 to 60 mg/m2, the dosage of these latter in the scope of the present invention is about 5 to 30 mg/m2,
- the usual daily dosage of vinblastine being from 5 to 7 mg/m2, the dosage of this latter in the scope of the present invention is about 1 to 4 mg/m2,
- the usual daily dosage of vincristin being from 1 to 2 mg/m2, the dosage of this latter in the scope of the present invention is about 0.1 to 1 mg/m2,
- the usual daily dosage of taxol being about 75 mg/m2, the dosage of this latter in the scope of the present invention is about 15 to 35 mg/m2.
- Among the cancers adapted to be treated in the scope of the present invention, can be cited principally:
- malignant hemopathies such as leukemias, lymphomas,
- solid tumors such as those of the ovary or the breast.
- The invention also has for its object any product containing:
- a compound inhibiting the activity of NF-κB such as described above, and more particularly a compound binding specifically to the transmembrane receptors of the class I cytokines as defined above,
- and a cytotoxic molecule adapted to activate the NF-κB factor,
- as a combined preparation for simultaneous use, separate or prolonged over time, for the treatment of malignant hemopathies and solid tumors.
- The invention also has for its object any product as defined above, as a combined preparation for simultaneous use, separate or over time, for the prevention of the appearance, or for the treatment, of phenomena of resistance to cytotoxic molecules used in the scope of treatment of the above-mentioned pathologies, appearing in patients treated with molecules when these latter are adapted to activate NF-κB.
- The invention relates more particularly to any product as defined above, characterized in that it comprises as a compound inhibiting the activation of NF-κB, growth hormone, prolactin, erythropoietin, interleukin-4, interleukin-7, G-CSF, GM-CSF, interleukin-3, interleukin-6.
- Products particularly preferred in the scope of the present invention, are those comprising as a compound inhibiting the activation of NF-κB, growth hormone or erythropoietin.
- The invention has more particularly for its object any product as defined above, characterized in that it comprises:
- human growth hormone obtained by extraction from hypophysary extracts, and purification,
- or, preferably, recombinant human growth hormone as described above, encoded by the nucleotide sequence
SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence of amino acids is represented bySEQ ID NO 2, or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequenceSEQ ID NO 2, and preserving the property of human growth hormone to inhibit the activation of NF-κB. - The invention also has for its object any product as defined above, characterized in that it comprises recombinant human erythropoietin such as described above encoded by the nucleotide sequence
SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented bySEQ ID NO 4, or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequenceSEQ ID NO 4, and preserving the property of human erythropoietin to inhibit the activation of NF-κB. - The invention also relates to any product as described above, characterized in that it comprises as cytotoxic molecule adapted to activate the NF-κB factor, any molecule selected from the following:
- cytokines,
- anthracyclines, such as daunomycin or dauxorubicin,
- vinca-alkaloids, such as vinblastine and vincristine,
- paclitaxel (or Taxol, DCI).
- Products such as those defined above that are preferred in the scope of the present invention, are characterized in that they contain:
- growth hormone and daunomycin or dauxorubicin, in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 5 to 30 mg/m2 of daunomycin or dauxorubicin,
- growth hormone and vinblastine, in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 1 to 4 mg/m2 of vinblastine,
- growth hormone and vincristine, in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 0.1 to 1 mg/m2 of vincristine,
- growth hormone and taxol, in proportions such that their daily dosage is about 2 IU/kg of growth hormone for about 15 to 35 mg/m2 of taxol,
- erythropoietin and daunomycin or dauxorubicin, in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 5 to 3 mg/m2 of daunomycin or dauxorubicin,
- erythropoietin and vinblastine, in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 1 to 4 mg/m2 of vinblastine,
- erythropoietin and vincristine, in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 0.1 to 1 mg/m2 of vincristine,
- erythropoietin and taxol, in proportions such that their daily dosage is about 150 IU/kg of erythropoietin for about 15 to 35 mg/m2 of taxol.
-
FIG. 1 : The effect of growth hormone on the mortality of cells exposed to α-TNF: the percentage of the dead cells (IP+) is indicated on the ordinate, the white colonies corresponding to the cells of the strain U937-Neo, the black colonies corresponding to the cells of the strain U937-hGH; the concentrations of NFT-α are indicated on the abscissa in IU/ml. -
FIG. 2 : The effect of growth hormone on the translocation of NF-κB;column 1 corresponds to the control cells U937,column 2 corresponds to the U937 cells treated with α-TNF+cycloheximide,column 3 corresponds to the U937 cells treated with α-TNF,column 4 corresponds to the U937 cells treated with α-TNF+a mutant NF-κB probe,column 5 corresponds to the U937 cells treated with α-TNF+a homologous NF-κB probe,column 6 corresponds to the control cells U937-HGH,column 7 corresponds to the U937-HGH cells treated with α-TNF+cycloheximide,column 8 corresponds to the U937-HGH cells treated with α-TNF; the presence of NF-κB is indicated by an arrow. -
FIG. 3 : Effect of growth hormone on the reporter activity CAT; the percentage of variation of CAT activity is indicated on the abscissa; the two left columns show the two experiments carried out on U937-Neo cells, and the two right columns represent the two independent experiments carried out on U937-HGH cells. -
FIG. 4 : Effect of growth hormone on apoptosis induced by daunomycin; the percentage of the dead cells (IP+) is indicated on the ordinate, the white columns corresponding to the cells of the strain U937-Neo, the black columns corresponding to the cells of the strain U937-HGH; the indicated percentages show the increase of mortality of the cells; the concentrations of daunomycin are indicated on the abscissa in μM. -
FIG. 5 : Effect of growth hormone on the apoptosis of the IGROV/ADR line, induced by daunomycin; the percentage of dead cells (IP+) is indicated on the ordinate, and different columns corresponding to the different concentrations of HGH used (0, 5, 50, 500, 1000 ng/ml); the concentrations of daunomycin are indicated on the abscissa in μM. -
FIG. 6 : Effect of erythropoietin on the apoptosis of the human renal carcinoma line HIEG, induced by daunomycin: for each of theexperiments - The invention is illustrated with the help of the following detailed description of the in vitro effect of growth hormone and erythropoietin on tumoral cell lines.
- A selection gene (neomycin resistant, NeOR) and the gene encoding for human growth hormone (HGH) have been co-transfected in the human promyeloid leukemic line U937. By comparing the transfected line U937-HGH (which produces in a constituent fashion HGH at physiologic doses), either to the parent line U937, or to a line transfected with NeoR alone, there are observed by different methodological approaches, that the U937-HGH line dies more under the effect of the tumor necrosis factor (α-TNF). This cytokine secreted by different types of immune cells has an anti-tumor activity (Harakana, K et al., 1984, Int J Cancer, 34:263-267) and is capable of promoting the activation of NF-κB (Baeuerle P A, Henkel T, 1994, Ann Rev Immunol, 12:141-179).
- The U937-HGH cells and the U937-Neo control cells have been cultured for 48 hours in the presence of increasing concentrations of recombinant α-TNF. As a result of this culture, the washed cells have been incubated in the presence of propidium iodide which is incorporated in the DNA of the dead cells. These cells are analyzed by flowing cytometry.
-
FIG. 1 shows the increase of the incorporation of propidium iodide as a function of increasing doses of α-TNF expressed in international units (IU). For the U937 cells (the mother line having served to obtain the U937-HGH lines), with increase of the concentration of α-TNF, there is observed a slight increase of the percentage of fluorescent cells (thus dead) due to the incorporation of propidium iodide (red fluorescence). This figure shows on the other hand clearly the fact that these values are much higher for the U937-HGH line, as a function of increasing doses of α-TNF added to the same culture. - It is thus demonstrated that the presence in the cellular cultures of HGH produced by the U937 lines transfected with the HGH gene, increases their susceptibility to the induction of death mediated by α-TNF.
- Having reported in a previous study that HGH could intervene in the inhibition of the activation of NF-κB mediated by lipopolysaccharides (Haeffner A et coll., 1997, J Immunol, 158:1310-1314), the inventors have studied the status of NF-κB during stimulation of the different lines by α-TNF.
-
FIG. 2 shows the result of an analysis by gel delay. On this gel were deposited nuclear extracts from the U937-HGH and U937 cells (the mother line having served for obtaining the U937-HGH lines) subjected to different inductors including α-TNF or α-TNF and cycloheximide (inhibitor of protein synthesis). This experiment indicates clearly that the presence of NF-κB in the nuclei of the U937-HGH cells, is decreased relative to the control cells. - The presence of NF-κB is seen in
lines -
FIG. 3 shows the result of an enzyme immunoassay (ELISA) carried out with the lysate of U937-HGH and U937-Neo cells transfected in a transitory manner with a plasmid containing NF-κB sequences in the promotor of the reporter gene encoding for chloramphenicol-acetyl-transferase (CAT) (Chiao P et coll., 1994, Proc Natl Acad Sci USA, 91:28-32). - The cells are transfected by electroporation then incubated with α-TNF. At the end of culturing, the cells are lysated and the activated CAT is measured by an commercial ELISA (Boehringer-Mannheim) according to the directions of the supplier.
- The figure shows that the CAT activity, reflected by the presence of NF-κB, is decreased in the U937-HGH cells relative to the control cells, after stimulation by α-TNF.
- The results shown in
FIGS. 2 and 3 therefore show by two different methodological approaches, that the synthesis of NF-κB is decreased in U937-HGH relative to the control line. - The use of α-TNF being very difficult in human clinical work because of the adverse side effects, the inventors are interested in daunomycin. This anthracyclin used in anti-cancer therapy under the name of Cerubidine□ acts by insertion in the cellular DNA sequences, thus disturbing the cellular function. Like α-TNF (Baeuerle P A, Henkel T, 1994, Ann Rev Immunol, 12:141-179), daunomycin activates NF-κB (Das K C, White C W, 1997, J Biol Chem, 272:14914-14920).
-
FIG. 4 indicates that the U937-HGH line is also more sensitive than the control line to the mediated death by daunomycin. - To test the possibility of using the object of the present invention on non-lymphoid tumors, the inventors have used HGH to try to invert the “adriamycine resistant” pheno-type of cells isolated from a human ovarian adenocarcinoma IGROV/ADR (Benard J et coll., 1985, Cancer Res, 45:4970-4979).
- As shown by
FIG. 5 , these cells are insensitive to the toxic effect of the daunomycin added to the culture (HGH groups 0 ng/ml). The addition of recombinant HGH (Saizen□, Serono laboratory) renders these cells sensitive to daunomycin, with a maximum effect observed for the lowest dose of HGH used here, namely 5 ml/ml. - These result proves on the one hand that the results of aggravated mortality can be obtained as well with recombinant exogenous HGH as with the transfected lines mentioned above, and that on the other hand, the present invention can be applied to non-lymphoid solid tumors.
- Erythropoietin (EPO), another molecule than HGH belonging to the same family of cytokines of class I, has been tested on human renal carcinoma cells (RCC) HIEG.
- 4.104 RCC cells have been transfected in a transitory manner with the help of an Effecten□ kit, or with 3 μg of plasmid carrying the gene encoding for EPO (RCC-EPO cells), or with 3 μg of a plasmid coding for the resistance to neomycin (RCC-Neo cells) as the negative control. After 48 hours, the RCC were combined with daunomycin at two different concentrations: 0.3 and 0.6 μM. The number of surviving cells was measured 48 hours later by flow cytometry (FIG. 6).
- The results of
Experiment 1 expressed in numbers of living cells are as follows:RCC-Neo RCC- EPO daunomycin 0 μM 14745 26911 daunomycin 0.3 μM 11382 3487 daunomycin 0.6 μM 10179 8551 - The results of
Experiment 2 expressed in numbers of living cells are as follows:RCC-Neo RCC- EPO daunomycin 0 μM 20150 29102 daunomycin 0.3 μM 8891 2693 daunomycin 0.6 μM 7001 4739 - The results show that in the two different experiments (
Experiments 1 and 2), the conjoint presence of daunomycin and EPO aggravates substantially the cellular mortality, with a more marked effect for the lower dose of daunomycin used.
Claims (6)
1. A method treating a patient having or subject to developing malignant hemopathies or solid tumors and/or to treat resistance to cytotoxic molecules of said treatments, comprising administering an effective amount of a compound that inhibits the activation of the nuclear factor κB (NF-κB).
2. The method according to claim 1 , further comprising one or several cytotoxic molecules usable in the scope of treatment of the above-mentioned pathologies and adapted to activate the NF-κB factor.
3. The method according to claim 2 , wherein said compounds inhibiting the activation of MF-κB are connected specifically to the transmembranal receptors of the cytokins of class I in the cells of the organism.
4. The method according to claim 1 , wherein said compound is a recombinant human erythropoietin such as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the help of vectors contained in a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification;
or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of inhibiting the activation of NF-κB.
5. The method according to claim 1 , wherein said compounds are in combination with one or several cytotoxic molecules adapted to activate the NF-κB factor, selected from:
cytokines,
anthracyclines, including daunomycin, and dauxorubicin,
vinca-alkaloids, such as vinblastine and vincristine,
paclitaxel (or Taxel, DCI).
6. The method according to claim 1 , said compound is administered with a dosage of the cytotoxic molecules used in combination with said compounds in about 2 to about 5 times less than the dosage of these same molecules used alone in the scope of treatment of malignant hemopathies and solid tumors.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/144,889 US20050272654A1 (en) | 1998-11-25 | 2005-06-06 | NF-kappaB activation inhibitors, and their pharmaceutical uses |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9814858A FR2786104B1 (en) | 1998-11-25 | 1998-11-25 | INHIBITORS OF NF-KB ACTIVATION, AND THEIR PHARMACEUTICAL USES |
FR98/14858 | 1998-11-25 | ||
US09/856,796 US6914046B1 (en) | 1998-11-25 | 1999-11-24 | NF-κB activation inhibitors, and their pharmaceutical uses |
PCT/FR1999/002897 WO2000030587A2 (en) | 1998-11-25 | 1999-11-24 | NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
US11/144,889 US20050272654A1 (en) | 1998-11-25 | 2005-06-06 | NF-kappaB activation inhibitors, and their pharmaceutical uses |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,796 Division US6914046B1 (en) | 1998-11-25 | 1999-11-24 | NF-κB activation inhibitors, and their pharmaceutical uses |
PCT/FR1999/002897 Division WO2000030587A2 (en) | 1998-11-25 | 1999-11-24 | NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050272654A1 true US20050272654A1 (en) | 2005-12-08 |
Family
ID=9533184
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,796 Expired - Fee Related US6914046B1 (en) | 1998-11-25 | 1999-11-24 | NF-κB activation inhibitors, and their pharmaceutical uses |
US11/144,889 Abandoned US20050272654A1 (en) | 1998-11-25 | 2005-06-06 | NF-kappaB activation inhibitors, and their pharmaceutical uses |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,796 Expired - Fee Related US6914046B1 (en) | 1998-11-25 | 1999-11-24 | NF-κB activation inhibitors, and their pharmaceutical uses |
Country Status (7)
Country | Link |
---|---|
US (2) | US6914046B1 (en) |
EP (1) | EP1131088A2 (en) |
JP (1) | JP2002537224A (en) |
AU (1) | AU1564300A (en) |
CA (1) | CA2351733A1 (en) |
FR (1) | FR2786104B1 (en) |
WO (1) | WO2000030587A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060167086A1 (en) * | 2003-02-14 | 2006-07-27 | Kazuo Umezawa | Medicinal composition |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |
AU2003244000A1 (en) * | 2002-06-26 | 2004-01-19 | Signal Creation Inc. | DRUG COMPOSITION CONTAINING NF-KappaB INHIBITOR |
GB0228441D0 (en) * | 2002-12-05 | 2003-01-08 | Ares Trading Sa | Splice variant |
EP3757570B1 (en) * | 2013-03-15 | 2023-10-11 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5725851A (en) * | 1990-04-10 | 1998-03-10 | Genentech, Inc. | Method and compositions for treating injury |
US5922674A (en) * | 1996-09-11 | 1999-07-13 | East Carolina University | Method of treatment using chemotherapy and erythropoietin |
US20020068690A1 (en) * | 1997-10-28 | 2002-06-06 | Albert S. Baldwin | Use of nf-kb inhibition in combination therapy for cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006040A1 (en) * | 1997-08-04 | 1999-02-11 | Berry Christopher J | Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof |
-
1998
- 1998-11-25 FR FR9814858A patent/FR2786104B1/en not_active Expired - Fee Related
-
1999
- 1999-11-24 WO PCT/FR1999/002897 patent/WO2000030587A2/en not_active Application Discontinuation
- 1999-11-24 AU AU15643/00A patent/AU1564300A/en not_active Abandoned
- 1999-11-24 EP EP99958229A patent/EP1131088A2/en not_active Withdrawn
- 1999-11-24 JP JP2000583472A patent/JP2002537224A/en active Pending
- 1999-11-24 US US09/856,796 patent/US6914046B1/en not_active Expired - Fee Related
- 1999-11-24 CA CA002351733A patent/CA2351733A1/en not_active Abandoned
-
2005
- 2005-06-06 US US11/144,889 patent/US20050272654A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5725851A (en) * | 1990-04-10 | 1998-03-10 | Genentech, Inc. | Method and compositions for treating injury |
US5922674A (en) * | 1996-09-11 | 1999-07-13 | East Carolina University | Method of treatment using chemotherapy and erythropoietin |
US20020068690A1 (en) * | 1997-10-28 | 2002-06-06 | Albert S. Baldwin | Use of nf-kb inhibition in combination therapy for cancer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060167086A1 (en) * | 2003-02-14 | 2006-07-27 | Kazuo Umezawa | Medicinal composition |
Also Published As
Publication number | Publication date |
---|---|
FR2786104B1 (en) | 2002-12-27 |
CA2351733A1 (en) | 2000-06-02 |
FR2786104A1 (en) | 2000-05-26 |
US6914046B1 (en) | 2005-07-05 |
EP1131088A2 (en) | 2001-09-12 |
WO2000030587A3 (en) | 2000-09-14 |
JP2002537224A (en) | 2002-11-05 |
WO2000030587A2 (en) | 2000-06-02 |
AU1564300A (en) | 2000-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lotem et al. | In vivo induction of normal differentiation in myeloid leukemia cells | |
Fujita et al. | Fibroblast‐dependent growth of mouse mast cells in vitro: duplication of mast cell depletion in mutant mice of W/Wv genotype | |
Morstyn et al. | Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. | |
Lu et al. | Protective influence of lactoferrin on mice infected with the polycythemia-inducing strain of Friend virus complex | |
JP2005029561A (en) | Antitumor agent containing consensus human leucocyte interferon | |
EP0493468B1 (en) | Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists | |
US5770190A (en) | Method of treatment of acute leukemia with inteleukin-10 | |
EP0131789A2 (en) | Composition comprising purified human tumour necrosis factor in conjunction with human interferon and its use | |
US5002879A (en) | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor | |
US20050272654A1 (en) | NF-kappaB activation inhibitors, and their pharmaceutical uses | |
US5208018A (en) | Treatment of cachexia with interleukin 2 | |
Saijo et al. | Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GMl antibody or anticancer agents | |
JPH09508116A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cytolytic activity | |
Talpaz et al. | Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis | |
Humphries et al. | An assessment of the effects of swainsonine on survival of mice injected with B16-F10 melanoma cells | |
US5560908A (en) | Therapeutic agent for NIDDM | |
Morris et al. | In vitro and in vivo effects of genistein on murine alveolar macrophage TNFα production | |
Bernell et al. | A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes | |
JP2784401B2 (en) | How to treat chronic myeloid leukemia | |
EP0248217B1 (en) | Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with lak cells and interleukin-2, of tumors | |
US5871725A (en) | Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity | |
Boyehansen et al. | Hematopoietic growth factors for the treatment of myelodysplastic syndromes | |
Nakano et al. | Accelerated recovery of antigen-presenting cell activity by the administration of interleukin 1α in 5-fluorouracil-treated mice | |
de Haan et al. | Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy | |
JPH08503001A (en) | Immune system and immune response enhancing compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |